Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Key Inclusion Criteria: * Genetically confirmed diagnosis of Alagille syndrome * History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument * Elevated serum bile acid level Key Exclusion Criteria: * History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma) * History of liver transplant, or a liver transplant is planned within 6 months of randomization * ALT \>10× upper limit of normal (ULN) at screening * Total bilirubin \>15 × ULN at screening * Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome